Atossa Therapeutics Inc. announced the issuance of a new patent in Israel for its Z-endoxifen program. The granted patent, No. 304863, covers high-purity Z-endoxifen enteric formulations, performance characteristics, and manufacturing methods. The protection includes oral, delayed-release dosage forms containing at least 90% by weight Z-endoxifen, specific impurity limits, defined release characteristics, various dose strengths, and pharmacokinetic performance targets. The company also received confirmation of the patent's renewal status from the Israel Patent Office.